Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | BHMT | Q93088 | 4/20 | 0.36 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.35 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.35 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | ARG1 | P05089 | 1/20 | 0.34 |
| ▸ | CTSC | P53634 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL27681989 | 1.00 | CYP3A4 (0.40) | CYP3A4SLC7A5CYP1A2BHMTBHMT2 | |
| Histidine SCHEMBL342892 | 1.00 | CYP3A4 (0.40) | CYP3A4SLC7A5CYP1A2BHMTBHMT2 | |
| Histidine SCHEMBL28650960 | 0.99 | CYP3A4 (0.40) | CYP3A4SLC7A5CYP1A2BHMTBHMT2 | |
| Histidine SCHEMBL27729896 | 0.95 | CYP3A4 (0.37) | CYP3A4SLC7A5CYP1A2BHMTBHMT2 | |
| Histidine SCHEMBL28888007 | 0.95 | CYP3A4 (0.37) | CYP3A4SLC7A5CYP1A2BHMTBHMT2 | |
| Histidine SCHEMBL23362634 | 0.94 | BHMT (0.39) | CYP3A4SLC7A5CYP1A2BHMTBHMT2 | |
| Histidine SCHEMBL28942432 | 0.94 | FNTA (0.38) | CYP3A4SLC7A5 | |
| Histidine SCHEMBL23362032 | 0.94 | CYP1A2 (0.42) | CYP3A4SLC7A5CYP1A2BHMTBHMT2 | |
| Histidine SCHEMBL1884290 | 0.94 | SLC7A5 (0.38) | CYP3A4SLC7A5CYP1A2BHMTBHMT2 | |
| Histidine SCHEMBL6805147 | 0.94 | SLC7A5 (0.38) | CYP3A4SLC7A5CYP1A2BHMTBHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 612 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115786296-B | Meso-diaminopimelate dehydrogenase mutant and production method thereof | 山东理工大学 | 2024-01-30 | — | — | CN | claimed |
| US-20230149516-A1 | USE OF PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR THERAPEUTIC PURPOSE | PAM THERAGNOSTICS GMBH (DE) | 2023-05-18 | — | — | US | claimed |
| US-20230097988-A1 | METHODS FOR DETERMINING PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) AND ITS USE FOR DIAGNOSTIC PURPOSE | PAM THERAGNOSTICS GMBH (DE) | 2023-03-30 | — | — | US | claimed |
| EP-4110372-A1 | USE OF PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR THERAPEUTIC PURPOSE | PAM Theragnostics GmbH (DE) | 2023-01-04 | — | — | EP | claimed |
| EP-4111201-A1 | METHODS FOR DETERMINING PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) AND ITS USE FOR DIAGNOSTIC PURPOSE | PAM Theragnostics GmbH (DE) | 2023-01-04 | — | — | EP | claimed |
| CN-115280148-A | Method for determining peptidylglycine alpha-amidating monooxygenase (PAM) and use thereof for diagnostic purposes | PAM治疗诊断有限公司 | 2022-11-01 | — | — | CN | claimed |
| CN-115243709-A | Use of peptidylglycine alpha-amidating monooxygenase (PAM) for therapeutic purposes | PAM治疗诊断有限公司 | 2022-10-25 | — | — | CN | claimed |
| WO-2019152516-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY OR AUTOIMMUNE DISEASES OR CONDITIONS USING CALCITONIN RECEPTOR ACTIVATORS | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2019-08-08 | — | — | WO | claimed |
| US-8883728-B2 | Intranasal administration of active agents to the central nervous system | AEGIS THERAPEUTICS, LLC (US) | 2014-11-11 | — | — | US | claimed |
| US-20110129462-A1 | INTRANASAL ADMINISTRATION OF ACTIVE AGENTS TO THE CENTRAL NERVOUS SYSTEM | AEGIS THERAPEUTICS LLC (US) | 2011-06-02 | — | — | US | claimed |
| EP-0493485-B1 | ERECTION-INDUCING METHODS AND COMPOSITIONS | SENETEK PLC (US) | 2001-12-19 | — | — | EP | claimed |
| EP-0822826-B1 | NITROSYLATED NEUROPEPTIDES | BRIGHAM & WOMENS HOSPITAL (US) | 2001-09-12 | — | — | EP | claimed |
| US-5770570-A | LIPOSOMES | PAUL SUDHIR (US) | 1998-06-23 | — | — | US | claimed |
| EP-0822826-A4 | — | — | 1998-02-25 | — | — | EP | claimed |
| EP-0822826-A1 | NITROSYLATED NEUROPEPTIDES | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1998-02-11 | — | — | EP | claimed |
| US-5612314-A | Nitrosylated neuropeptides | BRIGHAM & WOMEN'S HOSPITAL (US) | 1997-03-18 | — | — | US | claimed |
| WO-1996032954-A1 | NITROSYLATED NEUROPEPTIDES | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1996-10-24 | — | — | WO | claimed |
| US-5447912-A | Injecting the neuropeptides VIP and PHM and an adrenergic blocking agent | SENETEK, PLC (US) | 1995-09-05 | — | — | US | claimed |
| WO-1995005188-A1 | ERECTION-INDUCING METHODS AND COMPOSITIONS | SENETEK PLC (US) | 1995-02-23 | — | — | WO | claimed |
| US-5236904-A | ERECTION-INDUCING METHODS AND COMPOSITIONS | SENETEK, PLC (US) | 1993-08-17 | — | — | US | claimed |